CO6150163A2 - Composiciones adecuadas para administracion oral que comprende un derivado de triazolo [4,5-d] pirimidina - Google Patents

Composiciones adecuadas para administracion oral que comprende un derivado de triazolo [4,5-d] pirimidina

Info

Publication number
CO6150163A2
CO6150163A2 CO09017334A CO09017334A CO6150163A2 CO 6150163 A2 CO6150163 A2 CO 6150163A2 CO 09017334 A CO09017334 A CO 09017334A CO 09017334 A CO09017334 A CO 09017334A CO 6150163 A2 CO6150163 A2 CO 6150163A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
mixture
calcium phosphate
sodium
weight
Prior art date
Application number
CO09017334A
Other languages
English (en)
Inventor
Simon Banks
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39107049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6150163(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO6150163A2 publication Critical patent/CO6150163A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

1.- Una composición farmacéutica la cual comprende: {1S-[1a, 2a, 3ß(1S*,2R*) ,5ß] )-3-(7-{[2-(3,4-difluorofenil) ciclopropil]amino}-5-(propiltio)-3H-1,2,3-triazolo[4,5-d] pirimidin-3-il) -5-(2-hidroxietoxi) ciclopentano-1,2-diol; uno o más rellenos seleccionados a partir de manitol, sorbitol, dihidrato de fosfato de calcio dibásico, anhidro de fosfato de calcio dibásico y fosfato de calcio tribásico o una mezcla de los mismos; uno o más aglomerantes seleccionados entre hidroxipropilo celulosa, ácido algínico, carboximetilcelulosa sódica, copovidona y metilcelulosa o una mezcla de los mismos; uno o más desintegrantes seleccionados entre glicolato de almidón de sodio, croscarmelosa de sodio y crospovidona o una mezcla de los mismos;y uno o más lubricantes. 2.- Una composición farmacéutica tal cual se define en la reivindicación 1 en donde el relleno es una mezcla de manitol y dihidrato de fosfato de calcio dibásico. 3.- Una composición farmacéutica tal cual se define en la reivindicación 2 en donde el aglomerante es la hidroxipropilo celulosa. 4.- Una composición farmacéutica tal cual se define en la reivindicación 2 o la reivindicación 3 en donde el desintegrante es el glicolato de almidón de sodio. 5.- Una composición farmacéutica tal cual se define en cualquiera de las reivindicaciones 2 a 4 en donde el lubricante es seleccionado entre estearato de magnesio y fumarato de estearilo de sodio. 6.- Una composición farmacéutica tal cual se define en cualquiera de las reivindicaciones 2 a 5 en donde {1S-[1a, 2a, 3ß(1S*,2R*) ,5ß] )-3-(7-{[2-(3,4-difluorofenil) ciclopropil]amino}- 5-(propiltio)-3H-1,2,3-triazolo[4,5-d] pirimidin-3-il)-5-(2-hidroxietoxi) ciclopentano-1,2-diol está presente en una cantidad que oscila entre un 20 y 45% por peso. 7.- Una composición farmacéutica tal cual se define en cualquiera de las reivindicaciones 2 a 6 en donde el relleno está presente en una cantidad que oscila entre un 20 y 70% por peso. 8.- Una composición farmacéutica tal cual se define en cualquiera de las reivindicaciones 2 a 7 en donde el aglomerante está presente en una cantidad que oscila entre un 3 y 6% por peso.
CO09017334A 2006-08-21 2009-02-20 Composiciones adecuadas para administracion oral que comprende un derivado de triazolo [4,5-d] pirimidina CO6150163A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82308306P 2006-08-21 2006-08-21

Publications (1)

Publication Number Publication Date
CO6150163A2 true CO6150163A2 (es) 2010-04-20

Family

ID=39107049

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09017334A CO6150163A2 (es) 2006-08-21 2009-02-20 Composiciones adecuadas para administracion oral que comprende un derivado de triazolo [4,5-d] pirimidina

Country Status (35)

Country Link
US (2) US8425934B2 (es)
EP (1) EP2056832B1 (es)
JP (2) JP5385139B2 (es)
KR (1) KR101539467B1 (es)
CN (1) CN101505754A (es)
AR (1) AR062451A1 (es)
AU (2) AU2007288541B9 (es)
BR (1) BRPI0715712B8 (es)
CA (1) CA2659328C (es)
CL (1) CL2007002421A1 (es)
CO (1) CO6150163A2 (es)
CY (1) CY1119380T1 (es)
DK (1) DK2056832T3 (es)
ES (1) ES2625930T3 (es)
HR (1) HRP20170694T1 (es)
HU (1) HUE031939T2 (es)
IL (2) IL196700A (es)
LT (1) LT2056832T (es)
MX (1) MX340403B (es)
MY (2) MY175009A (es)
NO (1) NO341787B1 (es)
NZ (2) NZ574514A (es)
PH (1) PH12013501627A1 (es)
PL (1) PL2056832T3 (es)
PT (1) PT2056832T (es)
RS (1) RS55884B1 (es)
RU (2) RU2476223C2 (es)
SA (1) SA07280442B1 (es)
SG (1) SG177162A1 (es)
SI (1) SI2056832T1 (es)
TW (1) TWI482772B (es)
UA (1) UA99105C2 (es)
UY (1) UY30551A1 (es)
WO (1) WO2008024045A1 (es)
ZA (1) ZA200900991B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
BRPI0614410A2 (pt) 2005-08-15 2011-03-29 Boehringer Ingelheim Int processo para preparação de betamiméticos
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
WO2011076749A2 (en) 2009-12-23 2011-06-30 Ratiopharm Gmbh Solid pharmaceutical dosage form
CZ2012705A3 (cs) * 2012-10-16 2014-04-23 Zentiva, K.S. Pevná orální farmaceutická formulace obsahující ticagrelor
WO2014170026A1 (en) 2013-04-18 2014-10-23 Zentiva, K.S. Stabilized amorphous ticagrelor
EP2813216A1 (en) 2013-06-10 2014-12-17 Zentiva, a.s. Stabilized amorphous ticagrelor
CA2913326A1 (en) 2013-05-29 2014-12-04 Ratiopharm Gmbh Solid pharmaceutical dosage form
EP2816043A1 (en) 2013-06-21 2014-12-24 LEK Pharmaceuticals d.d. Spherical ticagrelor particles
WO2015001489A1 (en) 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Pharmaceutical compositions of ticagrelor
CZ2013866A3 (cs) 2013-11-08 2015-05-20 Zentiva, K.S. Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
CN104644604A (zh) * 2013-11-23 2015-05-27 天津市汉康医药生物技术有限公司 替格瑞洛倍半水合物胶囊及其制备方法
WO2015110952A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof
CN104940204A (zh) * 2014-03-27 2015-09-30 广东东阳光药业有限公司 一种替格瑞洛固体制剂及其制备方法
CN104098520B (zh) * 2014-07-23 2016-01-20 张远强 苯基三唑希夫碱类化合物、其制备方法和用途
KR20160012706A (ko) 2014-07-25 2016-02-03 동아에스티 주식회사 서방성 제제
CN105832683A (zh) * 2015-01-15 2016-08-10 成都国弘医药有限公司 一种含有替格瑞洛的片剂
WO2016120729A1 (en) * 2015-01-27 2016-08-04 Astrazeneca Ab Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
US11357742B2 (en) 2015-12-14 2022-06-14 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3389634B1 (en) 2015-12-14 2021-10-06 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP7055380B2 (ja) 2015-12-22 2022-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 免疫不全疾患を処置するための方法
CN105709230B (zh) * 2016-03-01 2019-05-31 北京鑫兰医药科技有限公司 一种替格瑞洛药物组合物及其制备方法
CA3019394A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
US20170296666A1 (en) 2016-04-18 2017-10-19 Amneal Pharmaceuticals Company Gmbh Stable Pharmaceutical Composition Of Amorphous Ticagrelor
CN107595789B (zh) * 2016-04-21 2021-01-15 阿斯利康(瑞典)有限公司 口腔崩解片
JP7084624B2 (ja) 2016-06-21 2022-06-15 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
EP3808748A1 (en) 2016-06-21 2021-04-21 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
EP3472129A4 (en) 2016-06-21 2019-12-04 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
TR201617983A2 (tr) 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Ti̇cagrelorun kati oral farmasöti̇k bi̇leşi̇mleri̇
EP3761965A1 (en) 2018-03-08 2021-01-13 Pharmaceutical Oriented Services Ltd Ticagrelor-containing tablet formulation
WO2020021110A1 (en) 2018-07-27 2020-01-30 Krka, D.D., Novo Mesto Pharmaceutical composition of ticagrelor
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
JP2022035920A (ja) 2020-08-19 2022-03-04 アストラゼネカ・アクチエボラーグ 併用療法
BR102021011533A2 (pt) * 2021-06-14 2022-12-27 Libbs Farmacêutica Ltda Composição farmacêutica e uso da composição farmacêutica
WO2024089196A1 (en) 2022-10-28 2024-05-02 Astrazeneca Ab Recombinant apyrase protein for use in the treatment of an ischemic event at a dose of 40-240 mg

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9904129D0 (sv) 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
WO2003053416A1 (en) * 2001-12-21 2003-07-03 Pfizer Products Inc. Directly compressible formulations of azithromycin
MXPA04007937A (es) 2002-02-15 2004-11-26 Biogal Gyogyszergyar Composicion en polvo que comprende zaleplon de distribucion de tamano de particula definida y productos farmaceuticos hechos a partir de los mismos.
US20040001885A1 (en) * 2002-06-27 2004-01-01 Unchalee Kositprapa Rapidly disintegrating antihistamine formulation
HN2003000272A (es) * 2002-09-10 2008-07-29 Pharmacia Italia Spa Formulaciones que comprenden un compuesto de indolinona
US20060039968A1 (en) 2002-10-08 2006-02-23 Ramalingam Manikandan Gabapentin tablets and method for their preparation
US20060189565A1 (en) * 2002-10-22 2006-08-24 Mathur Rajeev S Pharmaceutical compositions of ganciclovir
SE0203778D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
JP2005538038A (ja) * 2003-02-19 2005-12-15 テバ ジョジセルジャール レースベニュタールシャシャーグ 規定された粒子サイズの分布を持つザレプロンを含む粉末組成物、及びそれから作られた医薬製品
DE10319450A1 (de) 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
JP2005162696A (ja) * 2003-12-04 2005-06-23 Nichiko Pharmaceutical Co Ltd 溶出性に優れたセフジトレンピボキシル製剤
JP2007537184A (ja) 2004-05-13 2007-12-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗血小板剤に対する耐性を治療するためのジピリダモールの使用
WO2006072878A1 (en) 2005-01-07 2006-07-13 Ranbaxy Laboratories Limited Oral dosage forms of sertraline having controlled particle size and processes for their preparation
MX2007009196A (es) * 2005-01-31 2009-02-25 Optimer Pharmaceuticals Inc Compuestos macrocilicos de 18 miembros y analogos de los mismos.
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物

Also Published As

Publication number Publication date
MY175009A (en) 2020-06-02
IL196700A0 (en) 2009-11-18
SG177162A1 (en) 2012-01-30
NZ596700A (en) 2013-05-31
CA2659328C (en) 2015-08-11
ZA200900991B (en) 2010-02-24
BRPI0715712B1 (pt) 2021-03-23
JP5385139B2 (ja) 2014-01-08
HUE031939T2 (en) 2017-08-28
KR101539467B1 (ko) 2015-07-24
IL229130A0 (en) 2013-12-31
TWI482772B (zh) 2015-05-01
AU2007288541B2 (en) 2011-08-25
AU2007288541B9 (en) 2011-10-06
DK2056832T3 (en) 2017-05-22
JP2010501554A (ja) 2010-01-21
EP2056832A1 (en) 2009-05-13
BRPI0715712A2 (pt) 2014-06-24
IL196700A (en) 2014-08-31
NO341787B1 (no) 2018-01-22
US8425934B2 (en) 2013-04-23
RS55884B1 (sr) 2017-08-31
UA99105C2 (ru) 2012-07-25
NZ574514A (en) 2012-01-12
NO20090425L (no) 2009-03-05
UY30551A1 (es) 2008-03-31
PH12013501627A1 (en) 2014-11-10
US20130131087A1 (en) 2013-05-23
MX2009001853A (es) 2009-03-02
AU2007288541A1 (en) 2008-02-28
RU2476223C2 (ru) 2013-02-27
PL2056832T3 (pl) 2017-09-29
EP2056832A4 (en) 2012-12-26
CN101505754A (zh) 2009-08-12
MX340403B (es) 2016-07-07
CA2659328A1 (en) 2008-02-28
TW200817412A (en) 2008-04-16
JP2014040448A (ja) 2014-03-06
AU2011205164A1 (en) 2011-08-25
AU2011205164B2 (en) 2014-02-06
CL2007002421A1 (es) 2008-04-04
HRP20170694T1 (hr) 2017-07-28
WO2008024045A1 (en) 2008-02-28
BRPI0715712B8 (pt) 2021-05-25
RU2012153069A (ru) 2014-06-10
PT2056832T (pt) 2017-05-22
MY147966A (en) 2013-02-28
RU2009104330A (ru) 2010-09-27
KR20090055561A (ko) 2009-06-02
AR062451A1 (es) 2008-11-12
SA07280442B1 (ar) 2012-04-07
SI2056832T1 (sl) 2017-07-31
US20080058353A1 (en) 2008-03-06
EP2056832B1 (en) 2017-03-22
LT2056832T (lt) 2017-05-25
CY1119380T1 (el) 2018-02-14
ES2625930T3 (es) 2017-07-21

Similar Documents

Publication Publication Date Title
CO6150163A2 (es) Composiciones adecuadas para administracion oral que comprende un derivado de triazolo [4,5-d] pirimidina
DK200001170A (da) Farmaceutiske sammensætninger
EA200901277A1 (ru) Фармацевтические составы, содержащие пропиленгликольгидрат дапаглифлозина
PE20090964A1 (es) Derivados de pirrolo[2,3-d]pirimidina como inhibidores de proteina quinasa b
PE20100252A1 (es) Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
RU2002103603A (ru) Фармацевтические композиции, содержащие ингибитор hmg редуктазы
RS53570B1 (en) DPP IV INHIBITOR FORMULATIONS
ECSP088120A (es) Derivados de piridazinona como agonistas del receptorde la hormona tiroidea
ECSP088511A (es) Agonistas del receptor del neuropeptido-2
RU2016122609A (ru) Составы соединений азаиндола
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
PE20080376A1 (es) Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina derivado de fluorofenilpiridina
AR055015A1 (es) Derivados fusionados de pirazol composicion farmaceutica y uso del compuesto para fabricar medicamentos.
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
ECSP11011151A (es) Compuestos purina
CL2009000241A1 (es) Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
NO20070681L (no) 2, 4, 6-Trisubstituterte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse i behandling av kreft
GT200700103A (es) Compuestos biciclocarboxiamida sustituidos
NZ704171A (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
AR071721A1 (es) Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno.
PE20120990A1 (es) Formulaciones de alisquireno e hidroclorotiazida
ATE527991T1 (de) Pharmazeutische zusammensetzungen von pramipexol
WO2005118558A3 (de) Pyrimidinverbindungen und ihre verwendung